Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients

doi:10.3748/wjg.v21.i9.2746

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 9

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8065)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

487

WORD

282

HTML

4469

Figures (1-3)

162

Tables (1-2)

130

Sum=5530

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1242

Download

1293

Sum=2535

Mar 7, 2015 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Mar 7, 2015; 21(9): 2746-2753
Published online Mar 7, 2015. doi: 10.3748/wjg.v21.i9.2746

Full Size Figure Download Figure

Figure 2 Comparison of cumulative probability of complete virological response in patients undergoing therapy with tenofovir disoproxil fumarate or lamivudine plus adefovir. Tenofovir disoproxil fumarate (TDF) alone is represented by the medium weight line; lamivudine plus adefovir (LAM plus ADV) combination is shown by the dotted line; and both arms by the dashed line (P < 0.001). Baseline serum HBV DNA level showed no difference (P = 0. 639). LAM: Lamivudine; ADV: Adefovir; HBV: Hepatitis B virus.

Citation: Yang DH, Xie YJ, Zhao NF, Pan HY, Li MW, Huang HJ. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. World J Gastroenterol 2015; 21(9): 2746-2753
URL: https://www.wjgnet.com/1007-9327/full/v21/i9/2746.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i9.2746